Brazil's prioritising of generics could delay approval for innovators
This article was originally published in Scrip
Executive Summary
New, innovative medicines could eventually suffer delays in reaching the market if Brazil's medicines agency, ANVISA, continues to prioritise the registration of generic medicines, says the R&D based industry association, Interfarma.